Proteína tau como biomarcador en Alzheimer preclínico

Proteína tau como biomarcador en Alzheimer preclínico

El desarrollo de biomarcadores de la proteína tau para el diagnóstico temprano de la enfermedad de Alzheimer (EA) emerge como un desafío fundamental, pudiendo mejorar la efectividad de un tratamiento preventivo o que enlentezca la progresión de la enfermedad. Esta revisión analiza las evidencias qu...

Full description

Bibliographic Details
Main Authors:	Javiera Arriagada, Rocío Álvarez Villalobos
Format:	Article
Language:	English
Published:	Pontificia Universidad Católica de Chile 2022-06-01
Series:	ARS Medica
Subjects:	Alzheimer preclínico biomarcador plaquetas plasma proteína tau tau fosforilada
Online Access:	https://www.arsmedica.cl/index.php/MED/article/view/1892

Similar Items

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
by: Juan Lantero-Rodriguez, et al.
Published: (2024-02-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Prognostic value of cerebrospinal fluid biomarkers in mild cognitive impairment due to Alzheimer disease
by: R. López-Cuevas, et al.
Published: (2023-05-01)

Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings Proteína tau hiperfosforilada no líquido cefalorrraqueano de pacientes com doença de Alzheimer e outras demências: resultados preliminares
by: Ana Paula Barbosa Jeronimo Hartmann, et al.
Published: (2004-09-01)

Plasma tau complements CSF tau and P‐tau in the diagnosis of Alzheimer's disease
by: Silvia Fossati, et al.
Published: (2019-12-01)

Nanotechnology for tau pathology in Alzheimer's disease
by: Rongrong Ma, et al.
Published: (2024-08-01)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
by: Fernando Gonzalez-Ortiz, et al.
Published: (2023-03-01)

Toxic tau: structural origins of tau aggregation in Alzheimer's disease
by: Abdullah Al Mamun, et al.
Published: (2020-01-01)

Pathological Tau From Alzheimer’s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo
by: Jin Miao, et al.
Published: (2019-03-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-07-01)

Astrocytic Propagation of Tau in the Context of Alzheimer's Disease
by: Rebecca M. Fleeman, et al.
Published: (2021-03-01)

Platelet TAU is Associated with Changes in Depression and Alzheimer's Disease
by: Bettina Sarg, et al.
Published: (2022-05-01)

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
by: Edward N. Wilson, et al.
Published: (2022-11-01)

Péptido beta amiloide, proteína Tau y enfermedad de Alzheimer
by: Silvia Gra Menéndez, et al.
Published: (2002-12-01)

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
by: Javier Arranz, et al.
Published: (2024-06-01)

N368-Tau fragments generated by legumain are detected only in trace amount in the insoluble Tau aggregates isolated from AD brain
by: Kerstin Schlegel, et al.
Published: (2019-11-01)

Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation
by: Shweta Kishor Sonawane, et al.
Published: (2021-02-01)

INFLUÊNCIA DAS PROTEÍNAS BETA AMILOIDE E TAU NA DOENÇA DE ALZHEIMER
by: Fausto Pierdoná Guzen, et al.
Published: (2012-06-01)

A nonhuman primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau
by: Zhouquan Jiang, et al.
Published: (2024-01-01)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
by: Juan Lantero‐Rodriguez, et al.
Published: (2021-11-01)

Alzheimer’s disease brain contains tau fractions with differential prion-like activities
by: Longfei Li, et al.
Published: (2021-02-01)

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
by: Branislav Kovacech, et al.
Published: (2024-11-01)

Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
by: Yijun Chen, et al.
Published: (2023-07-01)

A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer’s disease brain
by: Ebru Ercan-Herbst, et al.
Published: (2019-12-01)

PET Imaging of Tau Pathology: Towards an affirmative diagnosis of Alzheimer’s and Tauopathies
by: Olga eJames, et al.
Published: (2015-03-01)

Two simple assays for assessing the seeding activity of proteopathic tau
by: Fei Liu, et al.
Published: (2023-04-01)

Plasma P-Tau181 for the Discrimination of Alzheimer’s Disease from Other Primary Dementing and/or Movement Disorders
by: John S. Tzartos, et al.
Published: (2022-08-01)

Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer’s Disease
by: Ioanna Tsantzali, et al.
Published: (2022-08-01)

P-tau217 as a Reliable Blood-Based Marker of Alzheimer’s Disease
by: Roy Lai, et al.
Published: (2024-08-01)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
by: Ruocheng Dong, et al.
Published: (2021-01-01)

Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimagingResearch in context
by: Stephanie Doering, et al.
Published: (2024-05-01)

Findings of 18F‐PI‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample
by: Shogyoku Bun, et al.
Published: (2022-12-01)

Tau Ubiquitination in Alzheimer's Disease
by: Longfei Li, et al.
Published: (2022-02-01)

Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease
by: Futao Zhou, et al.
Published: (2024-10-01)

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease
by: Xi-Lin Wu, et al.
Published: (2017-01-01)

Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platformResearch in context
by: Azadeh Feizpour, et al.
Published: (2024-11-01)

Plasma phospho-tau217 as a predictive biomarker for Alzheimer’s disease in a large south American cohort
by: Neetesh Pandey, et al.
Published: (2025-01-01)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
by: Gallen Triana‐Baltzer, et al.
Published: (2021-01-01)

Alzheimer's disease risk modifier genes do not affect tau aggregate uptake, seeding or maintenance in cell models
by: Sourav Kolay, et al.
Published: (2020-09-01)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
by: Juan Lantero-Rodriguez, et al.
Published: (2023-03-01)